21 Total results for product and free and sample content found
By Ljlal Syed, Mark Lansdell and David Abramson 28 Jul 2022
This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic
16 Jun 2022
The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information.
By Akriti Seth 17 Nov 2020
Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.
21 Oct 2020
Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.
15 Apr 2020
Gain a view into the market gaps, opportunities, and trends in biopharma with a look at deal-making from In Vivo. Examine how deal-making has impacted the industry and shifted market dynamics and learn how you can use knowledge of these trends to inform your own strategies.
By Jessica Merrill 08 Jan 2020
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
By Jessica Merrill 28 Nov 2019
Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.
By Vibha Ravi 13 Nov 2019
Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: